Abstract
Langerhans cell histiocytosis (LCH) is sometimes resistant to conventional chemotherapies, and treatment with 2-chlorodeoxyadenosine (2-CdA) is gaining importance as a salvage treatment for refractory or recurrent LCH. Secondary malignancies such as acute myelogenous leukemia and myelodysplastic syndrome (MDS) due to 2-CdA have recently been reported. However, there have been no reports to date of cases of 2-CdA-related secondary MDS in which spontaneous remission was achieved. Here, we report the case of a 1-year-old boy with an occipital tumor who was diagnosed with LCH by biopsy and underwent chemotherapy. However, the disease relapsed and became refractory to chemotherapy. He received 2-CdA treatment, which was effective. However 6 months after the start of treatment, he developed MDS with chromosomal abnormality of 7q−. After 1-year observation without any intervention, his hematological findings had returned to normal, and the chromosomal abnormality had also disappeared. To our knowledge, this is the first report of 2-CdA-related MDS with spontaneous hematological remission.
Similar content being viewed by others
References
Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CdA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. 1997;29:288–92.
Apollonsky N, Lipton JM. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol. 2009;31:53–6.
Weitzman S, Wayne AS, Arceci R, Lipton JM, Whitlock JA. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol. 1999;33:476–81.
Jager G, Hofler G, Linkesch W, Neumeister P. Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chlorodeoxyadenosine (2-CdA) treatement of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica. 2004;89:e1–3.
Van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Hagemeijer A, Scheiff JM, Bosly A, Straetmans N, Ferrant A. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br J Haematol. 1999;105:268–70.
Kroft SH, Tallman MS, Shaw JM, Thangavelu M, Peterson LC. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia. 1997;11:170.
Laurence FM, Zulian GB, Cabrol C, Betticher DC. Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiation therapy. Cancer Genet Cytogenet. 1997;99:85–9.
Delannoy A, Van den Neste E, Michaux JL, Bosly A, Ferrant A. Cladribine for Waldenstrom’s Macroglobulinaemia. Br J Haematol. 1999;104:933–4.
Kong LR, Huang CF, Hakimian D, Variakojis D, Klein L, Kuzel TM, Gordon LI, Zanzig C, Wollins E, Tallman MS. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin lymphoma. Cancer. 1998;82:957–64.
Parker TM, Klaassen RJ, Johnston DL. Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy. Cancer Genet Cytogenet. 2008;182:122–5.
Scheurlen W, Borkhardt A, Ritterbach J, Huppertz HI. Spontaneous hematological remission in a boy with myelodysplastic syndrome and monosomy 7. Leukemia. 1994;8:1435–8.
Leung EW, Woodman RC, Roland B, Abdelhaleem M, Freedman MH, Dror Y. Transient myelodysplastic syndrome associated with isochromosome 7q abnormality. Pediatr Hematol Oncol. 2003;20:539–45.
Renneboog B, Hansen V, Heimann P, De Mulder A, Jannsen F, Ferster A. Spontaneous remission in a patient with therapy-related myelodysplastic syndrome (t-MDS) with monosomy 7. Br J Haematol. 1996;92:696–8.
Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans’-cell histiocytosis. N Eng J Med. 2004;351:1034–5.
Henter JI, Karlen J, Calming U, Bernstrand C, Andersson U, Fadeel B. Successful treatment of Langerhans’-cell histiocytosis with etanercept. N Eng J Med. 2001;345:1577–8.
Weitzman S, Braier J, Egeler RM, Grois N, Ladisch S, Potschger U, Webb D, Whitlock J, Arceri RJ. 2′-Chlorodeoxyadenosine (2-CdA) as salvage for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer. 2009;53(7):1271–6.
Imamura T, Sato T, Shiota Y, Kanegane H, Kudo K, Nakagawa S, Nakadate H, Tauchi H, Kamizono J, Morimoto A. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol. 2010;91:646–51.
Yamada K, Yasui M, Sawada A, Inoue M, Nakayama M, Kawa K. Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain. Pediatr Blood Cancer. 2012;58:300–2.
Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME, Nicholson HS. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin N Am. 1998;12:369–78.
Petti MC, Latagliata R, Breccia M, Alimena G, Spadea A, D’Andrea M, Mancini M, Spiriti MAA, Mandelli F. Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event. Haematologica. 2001;86:1277–80.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Suzuki, D., Kobayashi, R., Sano, H. et al. Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis. Int J Hematol 97, 782–785 (2013). https://doi.org/10.1007/s12185-013-1343-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-013-1343-7